Flexion Therapeutics, Inc. (NASDAQ:FLXN) insider Michael D. Clayman acquired 5,000 shares of the stock in a transaction dated Wednesday, November 8th. The stock was purchased at an average cost of $23.60 per share, with a total value of $118,000.00. Following the purchase, the insider now directly owns 35,395 shares of the company’s stock, valued at $835,322. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Shares of Flexion Therapeutics, Inc. (NASDAQ:FLXN) traded up $0.13 on Friday, hitting $23.99. The company had a trading volume of 917,590 shares, compared to its average volume of 828,245. Flexion Therapeutics, Inc. has a 12 month low of $15.96 and a 12 month high of $32.25. The company has a current ratio of 12.93, a quick ratio of 18.29 and a debt-to-equity ratio of 0.87.

Flexion Therapeutics (NASDAQ:FLXN) last issued its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.11). sell-side analysts forecast that Flexion Therapeutics, Inc. will post -3.79 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Flexion Therapeutics, Inc. (FLXN) Insider Michael D. Clayman Acquires 5,000 Shares” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/11/10/flexion-therapeutics-inc-flxn-insider-michael-d-clayman-acquires-5000-shares.html.

A number of large investors have recently modified their holdings of FLXN. Bank of New York Mellon Corp lifted its stake in Flexion Therapeutics by 27.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 2,716,189 shares of the specialty pharmaceutical company’s stock valued at $54,921,000 after acquiring an additional 591,981 shares in the last quarter. State Street Corp lifted its stake in Flexion Therapeutics by 66.3% during the 2nd quarter. State Street Corp now owns 1,379,202 shares of the specialty pharmaceutical company’s stock valued at $27,888,000 after acquiring an additional 549,948 shares in the last quarter. Wasatch Advisors Inc. increased its position in shares of Flexion Therapeutics by 58.7% during the 2nd quarter. Wasatch Advisors Inc. now owns 1,018,219 shares of the specialty pharmaceutical company’s stock valued at $20,588,000 after purchasing an additional 376,745 shares during the last quarter. Nexthera Capital LP purchased a new stake in shares of Flexion Therapeutics during the 2nd quarter valued at $4,661,000. Finally, Pictet Asset Management Ltd. increased its position in shares of Flexion Therapeutics by 73.7% during the 2nd quarter. Pictet Asset Management Ltd. now owns 472,796 shares of the specialty pharmaceutical company’s stock valued at $8,080,000 after purchasing an additional 200,657 shares during the last quarter. Institutional investors and hedge funds own 72.04% of the company’s stock.

Several research analysts have recently issued reports on FLXN shares. BMO Capital Markets reaffirmed a “buy” rating on shares of Flexion Therapeutics in a research note on Friday, August 11th. Needham & Company LLC reaffirmed a “buy” rating and issued a $36.00 price objective (up previously from $34.00) on shares of Flexion Therapeutics in a research note on Thursday, August 10th. Wells Fargo & Company set a $39.00 price objective on Flexion Therapeutics and gave the company a “buy” rating in a research note on Friday, October 6th. Northland Securities reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Flexion Therapeutics in a research note on Wednesday, October 4th. Finally, Royal Bank Of Canada set a $44.00 price objective on Flexion Therapeutics and gave the company a “buy” rating in a research note on Monday, September 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $98.33.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Insider Buying and Selling by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.